-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Individuals with nonalcoholic steatohepatitis or elevated liver enzymes have increased cardiovascular mortality, but are often excluded from preventive trials
Vascular prevention
Recently, a research article was published in Eur Heart J, an authoritative journal in the cardiovascular field.
cardiovascular events
The study included 2,400 participants over the age of 50 who were randomly assigned to the intervention and control groups
diagnosis
In the original randomized population, 138 (11.
statistics
CONCLUSIONS: In patients receiving fixed-dose combination therapy, compound pills were safe and effective in preventing MCVE, even in participants with fatty liver and elevated liver enzymes
In patients receiving the fixed-dose combination therapy, the compound pill was safe and effective in preventing MCVE, even in participants with fatty liver disease and elevated liver enzymes
Original source:
Shahin Merat, et al.
Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial